Netherlands· NL-74775a94081d

Intuniv 3 mg tabletten met verlengde afgifte

A guanfacine product containing guanfacinehydrochloride, registered in Netherlands by Takeda Pharmaceuticals International AG Ireland Branch. The same ATC class is registered in 14 of our 19 countries.

ATC C02AC02

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about guanfacinehydrochlorideAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Guanfacine is registered in 14 of 19 countries.

Countries holding a registration under ATC C02AC02 (guanfacine), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
8 of them publish a price we can compare per daily dose

Search guanfacine products by name

Guanfacine · ATC C02AC02

14 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Germany
Icelandprice
Ireland
Netherlands
Norwayprice
Polandprice
Switzerlandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of guanfacine costs, country by country.

Normalised to the WHO defined daily dose (3 mg), the median price runs from $0.21 in United States to $7.74 in Switzerland — a ×37 gap.

2 markets with a comparable price for this class
Public list prices, converted to USD at the rate date shown
US figures are pharmacy acquisition cost (CMS NADAC), not retail

Open the full comparison — free account Drug prices for market access

Guanfacine · price per daily dose (3 mg)

USD · FX 28 Sept 2026

CH Switzerland$7.74
US United States$0.21 (acquisition cost)

Median listed price per WHO defined daily dose, in each market that publishes a price. US = pharmacy acquisition cost (CMS NADAC), not a retail price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)

Active substance: GUANFACINEHYDROCHLORIDE
Manufacturer: Takeda Pharmaceuticals International AG Ireland Branch
Country: Netherlands (NL)
ATC code: C02AC02
ATC class: Guanfacine
Defined daily dose: 3 mg, O
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
EU/1/15/1040

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

163 interactions on record for guanfacine.

Graded by severity as the source publishes them — 30 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check guanfacine against other medicines How interaction checks work

Guanfacine · interactions on record

163 records

30 severe
133 moderate

Most severe, free to view

AprepitantA04AD12severe
DexamethasoneH02AB02severe
KetoconazoleH02CA03severe
ChloramphenicolJ01BA01severe

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Guanfacine in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All guanfacine products

Authorised across Europe · EMA

The same active substance is authorised in 5 EEA countries. Names it is sold under:

Germany · Guanfacin Neuraxpharm
United Kingdom (Northern Ireland) · Guanfacine Crescent
Iceland · Intuniv, Paxneury
Liechtenstein · Intuniv, Paxneury
Norway · Intuniv, Paxneury

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/440c13d5-c5a6-49d5-b4ce-5f05f573d2ac
GET /v1/drugs/440c13d5-c5a6-49d5-b4ce-5f05f573d2ac?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tablet met verlengde afgifte",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/intuniv-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Guanfacine",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp115118",
  "excipients": [
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "COPOLYMEER VAN ETHYLACRYLAAT-METHACRYLZUUR (1:1)",
    "CROSPOVIDON (E 1202)",
    "FUMAARZUUR (E 297)",
    "GLYCEROLDIBEHENAAT",
    "HYPROMELLOSE 2208 (Release controlling polymer), K4M (E 464)",
    "IJZEROXIDE GEEL (E 172)",
    "INDIGOKARMIJN ALUMINIUMLAK (E 132)",
    "LACTOSE 1-WATER",
    "NATRIUMLAURILSULFAAT",
    "POLYSORBAAT 80 (E 433)",
    "POVIDON (E 1201)",
    "SILICIUMDIOXIDE (E 551)"
  ],
  "substances": [
    "GUANFACINEHYDROCHLORIDE"
  ],
  "leaflet_url": null,
  "authorised_at": "2015/09/17",
  "procedure_number": "EMEA/H/C/003759",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/15/1040",
  "additional_monitoring": "N"
}

API reference MCP server Plans

See everything about guanfacine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console